Neuro-Inflammation
Autoimmune brain inflammation is a leading treatable cause of rapidly progressive dementia
A Dutch multicenter study followed 147 adults presenting with dementia that developed within a year of symptom onset — a hallmark of rapidly progressive dementia. Autoimmune encephalitis turned out to be the single largest diagnostic category (39%) and the most common treatable cause (61% of treatable cases). Neurodegenerative diseases and Creutzfeldt-Jakob disease accounted for the bulk of untreatable cases. Seizures, often subtle and focal, were a strong tip-off — present in 34% of autoimmune cases versus 10% of others — most commonly tied to anti-LGI1 antibodies. Movement disorders that emerged within three months of symptom onset also pointed to autoimmune causes. The findings underscore that fast-moving cognitive decline warrants urgent workup including autoantibody testing, because early immunotherapy can reverse what looks initially like dementia. A subset of patients labeled as having dementia are actually carrying treatable inflammation.
Smell tissue reveals immune attack on the brain years before Alzheimer's symptoms
Loss of smell is one of the earliest warning signs of Alzheimer's disease, and researchers leveraged this by analyzing minimally invasive brush biopsies from the olfactory epithelium — accessible nasal tissue connected to brain regions affected earliest in Alzheimer's. Single-cell RNA sequencing on 22 subjects, including cognitively typical individuals with preclinical Alzheimer's biomarkers, revealed activated memory T cells, inflammatory myeloid cells, and signs of olfactory neuron injury already present before symptoms emerged. CD8 T-cell activation patterns in the nasal tissue paralleled those seen in cerebrospinal fluid of advanced Alzheimer's patients. The findings establish that neuroinflammation begins in tissue connected to the brain well before cognitive symptoms, and that a routine outpatient nasal biopsy may offer a window into early disease processes long hidden behind the inaccessibility of brain tissue itself.
Sleep deprivation weakens immunity and accelerates risk of neurodegenerative disease
Sleep is a core regulator of immune function, and persistent sleep loss measurably disrupts it. Research reviewed here shows that sleep deprivation alters white blood cell counts, reduces natural killer cell activity, impairs antibody production, and drives chronic inflammation. Acute deprivation produces compensatory changes that often reverse with recovery sleep, but chronic deprivation creates sustained immune dysregulation through stress pathways involving the hypothalamic-pituitary-adrenal axis, sympathetic nervous system, and gut-brain axis. The consequences extend beyond infection susceptibility: chronic sleep loss elevates risk for cardiovascular disease, diabetes, and neurodegenerative conditions including Parkinson's disease. The findings reinforce sleep as a non-negotiable pillar of brain protection, with both quality and duration mattering for long-term cognitive resilience.
Source: Zhou et al., Annals of Medicine and Surgery, 2025 — Sleep deprivation silently undermines immunity
Memory loss that mimics Alzheimer's but progresses differently identifies a distinct disease
Among 3,606 patients evaluated at a memory clinic, researchers used clinical criteria to identify those with limbic-predominant age-related TDP-43 encephalopathy (LATE) — a neurodegenerative disease that closely mimics Alzheimer's but follows a different course. About 1.6% met probable LATE criteria and 3.5% had co-occurring LATE and Alzheimer's. Compared to typical Alzheimer's patients, those with probable LATE alone declined more slowly across memory, attention, executive function, and visuospatial domains, and had lower mortality risk. Patients with both diseases combined declined faster than Alzheimer's alone. Imaging showed LATE patients had a distinctive pattern of relatively preserved hippocampus alongside temporal lobe atrophy. The findings highlight that what looks like Alzheimer's in older adults often involves multiple overlapping pathologies, each affecting prognosis and treatment response differently.
High-dose flu vaccine lowers Alzheimer's risk more than standard-dose
A retrospective study of nearly 165,000 U.S. adults aged 65 and older compared dementia outcomes among recipients of high-dose versus standard-dose inactivated influenza vaccines. Over up to three years of follow-up, high-dose recipients had significantly lower Alzheimer's dementia risk for the first 25 months post-vaccination, with effects strongest among women. The findings build on prior evidence that influenza vaccination itself is associated with reduced dementia risk, and suggest that enhanced immunogenic vaccines may offer additional protection — possibly through stronger defense against influenza-driven systemic inflammation that propagates to the brain, or through broader immune-modulating effects that dampen chronic neuroinflammation.
Mixed brain pathology produces overlapping symptom patterns from both diseases
Among 919 patients with autopsy-confirmed brain pathology, those with both Alzheimer's disease and frontotemporal lobar degeneration (FTLD) showed neuropsychiatric symptoms characteristic of each condition rather than one masking the other. Compared to FTLD alone, comorbid patients had over three times the odds of anxiety, plus elevated delusions and irritability. Compared to Alzheimer's alone, they showed three times the odds of personality change and double the odds of disinhibition. Roughly 30% of FTLD cases had comorbid Alzheimer's pathology. The findings suggest that when atypical behavioral symptoms appear alongside an established diagnosis, clinicians should consider whether a second neurodegenerative process is also at work.
A Simple Fingerstick Blood Test Accurately Detects Alzheimer's Disease Biomarkers
A large multi-center European study demonstrated that key Alzheimer's disease biomarkers — including phosphorylated tau 217 (p-tau217), GFAP, and neurofilament light — can be reliably measured from a few drops of capillary blood collected via fingerstick onto dried blood spot cards. Across 337 participants at 7 centers, p-tau217 levels from dried plasma spots correlated strongly with standard venous plasma results and predicted abnormal spinal fluid biomarker status with good accuracy. The method also worked in people with Down syndrome — a high-risk population — and initial findings showed that self-collected, unsupervised samples matched clinically collected ones, raising the possibility of remote, at-home testing for Alzheimer's detection.
Huber H, Montoliu-Gaya L, Brum WS, et al. A minimally invasive dried blood spot biomarker test for the detection of Alzheimer's disease pathology. Nature Medicine. 2026;32:599–608.
Brain Tau Scan and Simple Blood Test Perform Equally Well at Identifying Advanced Alzheimer's Pathology
A UCSF autopsy study of 73 dementia patients found that the FDA-approved tau PET scan (Flortaucipir) and a blood test measuring plasma p-tau217 performed with near-identical accuracy in detecting advanced Alzheimer's brain pathology, both achieving area-under-the-curve scores above 0.90. Both biomarkers were highly specific for Alzheimer's disease at Braak stages V–VI and high amyloid burden, but neither could reliably detect early or intermediate Alzheimer's changes in patients whose primary diagnosis was a different dementia. The findings support plasma p-tau217 as a practical, lower-cost screening alternative to PET imaging for identifying advanced Alzheimer's pathology.
Source: Vrillon A, Spina S, et al. medRxiv preprint. 2025. (Not yet peer-reviewed)
A Positive Blood Test for Alzheimer's Tau Is Not a False Alarm — Even in Other Dementias
A Harvard/Mass General autopsy study of 187 participants confirms that plasma pTau217 — a leading blood-based Alzheimer's biomarker — accurately reflects actual Alzheimer's brain pathology even when another dementia is the primary diagnosis. When pTau217 was elevated in patients with Lewy body disease, TDP-43, or vascular dementia, autopsy revealed that the vast majority also carried concurrent Alzheimer's changes. By contrast, GFAP was elevated across nearly all dementia types regardless of Alzheimer's pathology, making it a non-specific marker. NfL showed no consistent link to Alzheimer's pathology at all. These findings reframe how clinicians should interpret blood biomarker results in complex, mixed-pathology cases.
People With LATE Dementia Often Appear Cognitively Normal — Even as Brain Damage Accumulates
An autopsy-confirmed study of 686 older adults found that those with LATE — a TDP-43 brain disease distinct from Alzheimer's — were far more likely to appear cognitively intact at their initial clinical visit than those with Alzheimer's or combined disease. Over 40% of pure LATE patients were classified as cognitively normal at baseline, reported fewer memory complaints, and scored significantly better on neuropsychological testing. Symptoms emerged nearly six years later than in Alzheimer's patients. However, when LATE and Alzheimer's co-occurred, cognitive decline was dramatically accelerated — outperforming either disease alone across memory, language, processing speed, and executive function.
Source: Butler Pagnotti RM, et al. Neurology. 2023;100:e2027-e2035.
A Hidden Dementia Mimic Affects One in Three People Over 85 — And It's Not Alzheimer's
A consensus panel of leading neurologists has established the first clinical diagnostic criteria for LATE — limbic-predominant age-related TDP-43 encephalopathy — a progressive memory disorder affecting roughly a third of individuals over 85. LATE closely mimics Alzheimer's disease with hippocampal atrophy and episodic memory loss, yet it follows a slower, more isolated course and does not respond to anti-amyloid therapies. When LATE co-occurs with Alzheimer's, cognitive decline accelerates significantly. The criteria distinguish "probable" LATE (amyloid-negative) from "possible" LATE (amyloid-positive but with disproportionate hippocampal damage), offering clinicians a framework for more accurate diagnosis and treatment decisions.
Source: Wolk DA, Nelson PT, et al. Alzheimer's & Dementia. 2025;21:e14202.
Spinal Fluid Tau Markers Signal Alzheimer's Brain Changes Up to 13 Years Before Symptoms
A Johns Hopkins study of 120 cognitively unimpaired adults found that rising levels of phosphorylated tau (p-tau181) and total tau in cerebrospinal fluid were strongly linked to future tau accumulation in the brain's memory regions — specifically the entorhinal cortex and hippocampus, the earliest areas affected in Alzheimer's disease. Tracked over an average of 12.8 years, participants with steeper CSF tau trajectories showed significantly greater tau PET burden in Braak stage I and II regions. These findings suggest that spinal fluid biomarkers may serve as an early warning system for tau pathology long before any cognitive symptoms appear, offering a critical window for intervention.
Sensory Gamma Stimulation: A New Frontier in AD Treatment
This essay explores the innovative use of noninvasive sensory stimulation—specifically 40-Hz (Gamma) light and sound—to combat Alzheimer’s Disease (AD). Pioneered by researchers at MIT, this approach, known as GENUS (Gamma Entrainment Using Sensory Stimuli), has demonstrated the ability to reduce amyloid and tau levels and prevent neuronal loss in animal models. The stimulation works by "entraining" brain rhythms, which in turn recruits microglia (the brain's immune cells) to become more active in clearing pathological proteins and widening the diameter of brain blood vessels to improve waste clearance. Preliminary human trials show that the treatment is safe, well-tolerated, and can strengthen functional connectivity between brain regions. By leveraging the brain's natural electrical rhythms to drive biological repair, 40-Hz stimulation represents a cutting-edge intervention within the Neuro-Inflammation and Physical Foundations pillars.
Gamma Music-Based Interventions and Dementia Pathophysiology
This review explores the therapeutic potential of combining music-based interventions (MBIs) with Gamma-frequency stimulation (e.g., 40 Hz) to treat Alzheimer’s disease. Emerging research suggests that Gamma-frequency sensory stimulation can remediate multiple pathophysiologies, including the reduction of amyloid plaques and tau tangles, while restoring neural oscillations. By integrating these rhythmic stimuli into music, researchers hypothesize a synergistic effect that engages auditory-reward networks and promotes neuroprotection. This dual approach aims to bridge molecular-level repair with systems-level cognitive improvement. By modulating neural firing patterns and enhancing waste clearance, Gamma MBIs offer a non-invasive strategy to support the Neuro-Inflammation and Physical Foundations pillars of brain health.
AS01-Adjuvanted Vaccination and Lower Risk of Dementia
This large-scale propensity-score matched cohort study investigated the association between AS01-adjuvanted vaccines and dementia risk. By analyzing over 430,000 individuals, researchers found that both the recombinant shingles vaccine (Shingrix) and the recently introduced RSV vaccine—both of which utilize the AS01 adjuvant system—were associated with a significantly lower 18-month risk of dementia compared to non-adjuvanted vaccines. Because the protective effect was consistent across different pathogens (Varicella-Zoster and RSV), the findings suggest that the AS01 adjuvant itself may exert direct neuroprotective effects. The mechanism likely involves the systemic modulation of the innate immune system, potentially resolving chronic low-grade inflammation. By leveraging specific vaccine technologies to dampen maladaptive immune responses, this intervention targets Neuro-Inflammation to preserve long-term cognitive health.